

A microwell platform to standardize human rectal organoid cultures for high-content imaging and phenotypic analyses

Meyer, M.¹, Clapés, M.¹, Sirenko, O.², Lim, A.², Storm, R.³, Brandenburg, N.¹

¹SUN bioscience SA, Lausanne, Switzerland. ²Molecular Devices LLC, San Jose, United States. ³Molecular Devices (UK) Ltd, United Kingdom.


INTRODUCTION

Organoids are three-dimensional (3D), self-organizing *in vitro* cell culture organ models. These 3D structures derive from stem cells and harbor key features of their native organs. Since the development of the first mouse intestinal organoids in 2009, a large variety of organoid models have been established¹. However, they still heavily rely on the use of solid extracellular matrix (ECM). This conventional culture method introduces a high level of heterogeneity, both in terms of size, shape and distribution of the organoids, which complicates subsequent downstream readouts and image analyses². To overcome these challenges and closely follow organoid development, we use our innovative technology Gri3D[®], a ready-to-use platform for high-throughput and reproducible 3D cultures³. This platform enables the homogenous generation of a single microtissue in each microcavity in suspension-like conditions, without the need of a solid ECM. The organoids are positioned in predefined locations and on the same focal plane, allowing simultaneous tracking at high resolution. Combined with the ImageXpress[®] Micro Confocal system, we follow the development and self-organization of human rectal organoids over time and investigate the effects of a small panel of compounds using brightfield image analyses and fluorescence-based readouts.

METHODS

Human rectal organoids are generated in Gri3D[®] g6WP imaging-bottom 500 µm microwells (SUN bioscience) starting from a single cell suspension and cultured for up to 7 days. Organoid development is followed over time with TL imaging on an ImageXpress[®] Micro Confocal system (Molecular Devices). In parallel, we compare organoids cultured on Gri3D[®] or embedded in solid-ECM drops using IN-Carta[®] Image Analysis Software. Finally, Live/Dead assay is performed on compound-treated organoids and analysed using IN-Carta[®] and in-house developed image analyses pipelines.

GRI3D[®] TECHNOLOGY



Gri3D[®] is a ready-to-use platform for high-throughput and reproducible organoid culture. Based on an array of ultra-dense U-bottom microwells in a hydrogel, single organoids are robustly generated in each microcavity and grown in suspension-like culture without a solid ECM.



RESULTS

Human rectal organoids cultured on Gri3D[®] are imaged over 7 days (Fig.1 A). Organoids rapidly form a lumen and differentiate in the microcavities, showing budding already after 4 days. Using a machine learning image-based approach on TL images, we efficiently detect each single organoid and quantify growth over time (Fig 1. B). When compared to solid-ECM grown organoids, Gri3D[®] cultures show higher homogeneity in terms of size and positioning (Fig. 2 A and B). Organoid differentiation is promoted only on Gri3D[®], and while budding increases the area, it decreases the shape factor (Fig. 2 C and D). Upon exposure to a small panel of compounds known for their intestinal toxicity, Live/Dead assay shows a viability decrease of organoids with increasing concentrations of mitomycin C and doxorubicin (Fig. 3 A). All compounds but cisplatin hamper the development and growth of intestinal organoids, stopping or reducing organoid growth (Fig. 3 B).






Figure 3. Response of human rectal organoids exposed to a panel of intestinal toxicity compounds. Live/Dead assay is performed on 6-day old organoids grown on Gri3D[®] after 72 hours exposure to the drugs. **A.** Ethidium homodimer-1 (EthD-1) to Calcein AM intensity ratio. Error bars show standard deviation. Each dot represents an organoid. **B.** Organoid area over time during exposure to the highest concentrations (30 µM) of the compounds. **C.** Maximum projection images of organoids after Live/Dead assay. Green: Calcein AM, live; red: EthD-1, dead. One-way ANOVA Dunnett's multiple comparisons, ***P < 0.001, P**** < 0.0001, ns: non-significant. Scale bar: 500 µm.



CONCLUSIONS

- Based on a 96 well plate format, Gri3D[®] 500 µm microwells allows the homogenous and robust generation of more than 70 organoids per well.
- Gri3D[®] is a front-to-end solution for high-content imaging of organoids enabling phenotypic-based screening workflows.
- The combination of Gri3D[®] technology and a high-content imaging system allows the characterization of single organoids in one plane.
- The reported drug toxicity assessment workflow enables *in vitro* studies of human rectal organoids in high-throughput.
- Our innovative approach has high potential in solving key challenges related to 3D cultures and compound assessment at large scale using patient-derived samples.

REFERENCES

1. Kim, J., Koo, BK. & Knoblich, J.A. Human organoids: model systems for human biology and medicine. *Nat Rev Mol Cell Biol* 21, 571–584 (2020).
2. Fatehullah, A., Tan, S. & Barker, N. Organoids as an *in vitro* model of human development and disease. *Nat Cell Biol* 18, 246–254 (2016).
3. Brandenburg, N. *et al.* High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. *Nat. Biomed. Eng.* 4, 863–874 (2020).